Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01774695
Other study ID # VGFOUSA-181101
Secondary ID
Status Completed
Phase N/A
First received January 8, 2013
Last updated January 21, 2013
Start date June 2011
Est. completion date November 2011

Study information

Verified date January 2013
Source Sahlgrenska University Hospital, Sweden
Contact n/a
Is FDA regulated No
Health authority Sweden: Swedish National Council on Medical Ethics
Study type Interventional

Clinical Trial Summary

Increased physical activity has in the investigators recent study been shown to improve symptoms in irritable bowel syndrome (IBS). The aim of this study was to assess the long term effects of the investigators previous intervention in IBS patients to improve physical activity. The investigators aimed to assess the long term effects on IBS symptoms as well as quality of life, fatigue, depression and anxiety.


Description:

86 patients who had been included in the investigators previous study "Physical Activity Improves Symptoms in Irritable Bowel Syndrome: A Randomized Controlled Trial" were contacted and asked to participate in a long term follow up 5 years after the previous study. The subjects attended one visit at which they underwent a bicycle ergometer test to calculate the oxygen uptake and filled out questionnaires.


Recruitment information / eligibility

Status Completed
Enrollment 39
Est. completion date November 2011
Est. primary completion date September 2011
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Baseline data from the previous study

Exclusion Criteria:

- pregnancy

- organic gastrointestinal disorders

- cardiac disease

- respiratory disease

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Behavioral:
Increased physical activity
The subjects were encouraged to increase their level of physical activity for 12 weeks in the previous study. The advice was individual but was based on the recommendations of the Swedish National Institute of health. The recommendation for increasing cardiorespiratory fitness is 20-60 minutes of moderate to vigorous intensive physical activity 3 to 5 days per week.

Locations

Country Name City State
Sweden Dept of Internal Medicine, Sahlgrenska University Hospital Gothenburg

Sponsors (1)

Lead Sponsor Collaborator
Sahlgrenska University Hospital, Sweden

Country where clinical trial is conducted

Sweden, 

References & Publications (1)

Johannesson E, Simrén M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am J Gastroenterol. 2011 May;106(5):915-22. doi: 10.1038/ajg.2010.480. Epub 2011 Jan 4. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Oxygen uptake The oxygen uptake was calculated from a submaximal cycle (Monark Ergomedic 839). ergometer test according to Astrand. Change between baseline and at follow up after 5 years No
Primary IBS Severity Scoring System (IBS-SSS) The IBS-SSS consists of visual analog scales and is divided into two subscales, an overall IBS score and an extra colonic score. The IBS score contains questions regarding pain severity, pain frequency, abdominal bloating, bowel habit dissatisfaction, and life interference. The extra colonic score contains questions regarding vomiting, gas, belching, satiety, headache, fatigue, musculoskeletal pain, heartburn, dysuria and urgency. Each subscale ranges from 0 to 500, with higher scores meaning more severe symptoms. A reduction of 50 is considered to be adequate to detect a clinical improvement. Change between baseline and follow up after five years No
Secondary Hospital Anxiety and Depression Scale (HADS) HADS was developed for medical outpatients and consists of 14 items, each using a 4-graded Likert scale (0-3). The scale is divided into two subscales, anxiety and depression. Each subscale ranges from 0 to 21, where high score means more severe symptoms. Change between baseline and follow up after 5 years No
Secondary IBS Quality of Life (IBS-QoL) The IBS-QOL is a disease specific instrument measuring HRQOL. It consists of 30 items which measures nine dimensions; emotional functioning, mental health, sleep, energy, physical functioning, diet, social role, physical role and sexual relations. For each subscale the scores are transformed to range from 0 to 100; 100 representing the best possible disease specific quality of life. Change between baseline and follow up after 5 years No
Secondary Short Form 36 (SF-36) SF-36 was used to assess the general HRQOL. SF-36 includes 36 items which are divided into eight subscales; physical functioning, physical role, body pain, general health perceptions, vitality, social functioning, emotional role and mental health. For each subscale the raw scores are transformed into a scale from 0 to 100, with 100 representing the best possible HRQOL. Change between baseline and follow up after 5 years No
Secondary Fatigue Impacts Scale(FIS) This scale was initially developed for patients with chronic fatigue syndrome and has previously been used in studies in IBS patients.11 The scale consists of 40 questions divided into three subscales, physical functioning (10 items), cognitive functioning (10 items) and psychosocial functioning (20 items). The subjects are asked to rate to which extent fatigue has caused problems for them during the previous month. Each item consists of a statement and the subject should rate 0 to 4 where 0 means 'no problem' and 4 means 'extreme problem'. Change between baseline and follow up after 5 years No
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05795049 - Genetic Carbohydrate Maldigestion as a Model to Study Food Hypersensitivity
Withdrawn NCT02841878 - Genetic Determinism of Epithelial Barrier Defects in Irritable Bowel Syndrome N/A
Completed NCT02875847 - Effects of HMOs on Faecal Microbiota, Gastrointestinal Symptoms, Mucosal Immunity and Barrier Function in IBS Patients Phase 2
Completed NCT02842281 - Microbiome Fructan Metabolism and Symptoms in Childhood IBS N/A
Completed NCT02092402 - Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome N/A
Completed NCT03964103 - qQ-lab Daily-IBS for Irritable Bowel Syndrome N/A
Completed NCT00401479 - A Study To Investigate The Effect Of Solabegron (GW427353) On Gastrointestinal Transit In Healthy Volunteers Phase 1
Completed NCT00421707 - Randomized Placebo Controlled Efficacy And Safety Study Investigating GW876008 In Patients With Irritable Bowel Syndrome Phase 2
Not yet recruiting NCT06139744 - Efficacy and Safety of Dietary Supplementation of Diamine Oxidase to Improve Symptoms in Patients With IBS Phase 4
Recruiting NCT04506593 - Indiana University Gastrointestinal Motility Diagnosis Registry
Completed NCT01908465 - Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial Phase 4
Completed NCT01787253 - Microbe-Gut Interaction in Microscopic Colitis and Post-Infectious Irritable Bowel Syndrome (IBS)
Completed NCT00376896 - Study On The Effect Of GW876008 On Cerebral Blood Flow In Irritable Bowel Syndrome (IBS) Patients And Healthy Volunteers Phase 1
Not yet recruiting NCT05630703 - Mindfulness Training Versus Low (FODMAP) Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols Diet N/A
Completed NCT00904696 - Tolerability and Effectiveness of Progut in Treatment of Irritable Bowel Syndrome N/A
Recruiting NCT05453084 - Exercise and Irritable Bowel Syndrome (IBS) N/A
Completed NCT03550742 - Effect of HMOs as Nutritional Support for Normal Bowel Movements in IBS Patients N/A
Terminated NCT01887002 - Study to Evaluate the Effects of ONO-2952 on Pain Perception Produced by Rectal Distention in Female Subjects With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Phase 2
Completed NCT01204515 - Abdominal Symptom Phenotype Study in Children N/A
Completed NCT00067457 - Study In Women With Severe Diarrhea-Predominant Irritable Bowel Syndrome Having Failed Conventional Therapy Phase 3